S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Buy THIS stock before Taiwan is attacked (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Buy THIS stock before Taiwan is attacked (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
BREAKING: Tiny biotech successfully treats blindness (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Buy THIS stock before Taiwan is attacked (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Buy THIS stock before Taiwan is attacked (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
BREAKING: Tiny biotech successfully treats blindness (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Buy THIS stock before Taiwan is attacked (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Buy THIS stock before Taiwan is attacked (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
BREAKING: Tiny biotech successfully treats blindness (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Buy THIS stock before Taiwan is attacked (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Buy THIS stock before Taiwan is attacked (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
BREAKING: Tiny biotech successfully treats blindness (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:IMTX

Immatics (IMTX) Stock Forecast, Price & News

$9.85
+0.40 (+4.23%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$9.17
$9.93
50-Day Range
$5.92
$10.10
52-Week Range
$5.90
$13.60
Volume
212,300 shs
Average Volume
318,463 shs
Market Capitalization
$755.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.75

Immatics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.5% Upside
$19.75 Price Target
Short Interest
Bearish
8.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.92mentions of Immatics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.41) to ($1.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

Medical Sector

940th out of 1,010 stocks

Biological Products, Except Diagnostic Industry

156th out of 169 stocks


IMTX stock logo

About Immatics (NASDAQ:IMTX) Stock

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Stock News Headlines

Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Immatics (IMTX) Gets a Buy from Mizuho Securities
Jefferies Keeps Their Buy Rating on Immatics (IMTX)
SVB Securities Keeps Their Buy Rating on Immatics (IMTX)
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
What's Going On With Immatics Shares Today
Immatics (NASDAQ:IMTX) Trading 7.1% Higher
Immatics N.V.
Immatics (NASDAQ:IMTX) Sees Unusually-High Trading Volume
Immatics (NASDAQ:IMTX) Coverage Initiated by Analysts at Mizuho
Immatics (IMTX) Initiated with a Buy at Mizuho Securities
Immatics (NASDAQ:IMTX) Trading 5.2% Higher
See More Headlines
Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Company Calendar

Last Earnings
3/21/2023
Today
5/29/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMTX
Fax
N/A
Employees
188
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.75
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+100.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$39.53 million
Pretax Margin
-88.57%

Debt

Sales & Book Value

Annual Sales
$182.13 million
Cash Flow
$0.61 per share
Book Value
$2.93 per share

Miscellaneous

Free Float
N/A
Market Cap
$755.20 million
Optionable
Not Optionable
Beta
0.44

Key Executives

  • Dr. Harpreet Singh Ph.D. (Age 47)
    CEO, MD, Member of Management Board & Supervisory Director
  • Dr. Hans-Georg Rammensee Ph.D.
    Co-Founder & Member of the Scientific Advisory Board
  • Dr. Toni Weinschenk Ph.D. (Age 49)
    Co-Founder & Chief Innovation Officer
  • Mr. Arnd Christ MBA (Age 56)
    Chief Financial Officer
  • Mr. Steffen Walter Ph.D. (Age 46)
    Chief Technology Officer
  • Mr. Edward A. Sturchio
    Gen. Counsel & Sec.
  • Ms. Anja Heuer B.Sc.
    Director of Corp. Communications
  • Ms. Tamara Louw M.B.A.
    P.H.R., Sr. Director of HR
  • Dr. Carsten Reinhardt M.D. (Age 55)
    Ph.D., Chief Devel. Officer
  • Dr. Rainer Kramer Ph.D. (Age 57)
    Chief Bus. Officer & Site Head Munich













IMTX Stock - Frequently Asked Questions

Should I buy or sell Immatics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings
or view top-rated stocks.

What is Immatics' stock price forecast for 2023?

4 brokerages have issued 1-year price targets for Immatics' stock. Their IMTX share price forecasts range from $12.00 to $26.00. On average, they expect the company's stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 100.5% from the stock's current price.
View analysts price targets for IMTX
or view top-rated stocks among Wall Street analysts.

How have IMTX shares performed in 2023?

Immatics' stock was trading at $8.71 at the beginning of the year. Since then, IMTX shares have increased by 13.1% and is now trading at $9.85.
View the best growth stocks for 2023 here
.

Are investors shorting Immatics?

Immatics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,420,000 shares, an increase of 28.1% from the April 30th total of 3,450,000 shares. Based on an average daily volume of 370,900 shares, the short-interest ratio is presently 11.9 days. Currently, 8.1% of the company's shares are sold short.
View Immatics' Short Interest
.

When is Immatics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our IMTX earnings forecast
.

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) posted its earnings results on Tuesday, March, 21st. The company reported ($0.23) EPS for the quarter. The business earned $38.44 million during the quarter, compared to analysts' expectations of $13.18 million. Immatics had a negative net margin of 85.93% and a negative trailing twelve-month return on equity of 41.31%.

What ETFs hold Immatics' stock?

ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC),

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).

What is Immatics' stock symbol?

Immatics trades on the NASDAQ under the ticker symbol "IMTX."

Who are Immatics' major shareholders?

Immatics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.87%), Price T Rowe Associates Inc. MD (0.77%), Braidwell LP (0.42%), JPMorgan Chase & Co. (0.29%), Hudson Bay Capital Management LP (0.28%) and Governors Lane LP (0.17%).

How do I buy shares of Immatics?

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immatics' stock price today?

One share of IMTX stock can currently be purchased for approximately $9.85.

How much money does Immatics make?

Immatics (NASDAQ:IMTX) has a market capitalization of $755.20 million and generates $182.13 million in revenue each year. The company earns $39.53 million in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does Immatics have?

The company employs 188 workers across the globe.

How can I contact Immatics?

Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 4.97072E+12.

This page (NASDAQ:IMTX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -